Failure of the bethanechol supersensitivity test to predict improved voiding after subcutaneous bethanechol administration.
Subcutaneous administration of 5 mg. bethanechol chloride did not change significantly either flow rates or percentage residual urine in 11 patients with a positive bethanechol supersensitivity test. Therefore, a positive response to this test cannot be used to predict improved voiding function after subcutaneous or oral administration of the drug. Studies that purport to show a long-term rather than a short-term facilitory effect of this agent on voiding must satisfy rigid criteria, which include totally excluding a change in any other factor affecting the lower urinary tract.
D001626:Bethanechol Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D001745:Urinary Bladder Diseases / Q000188:drug therapy* / Q000503:physiopathology; D014554:Urination; D014563:Urodynamics
D001626:Bethanechol Compounds